Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Zealand Pharma A/S (Nasdaq: ZEAL) announced transactions in its shares by persons in managerial roles and their associates, as per corporate governance guidelines. The company focuses on innovative peptide-based medicines, with a pipeline featuring three late-stage drug candidates. Zealand's notable products include V-Go® and Zegalogue®. The press release emphasizes the company's commitment to enhancing patient care through peptide therapeutics, supported by collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals.
- Robust pipeline with three candidates in late-stage development.
- Marketed products include V-Go® and Zegalogue®.
- Collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals expand market potential.
- None.
Company announcement – No. 38 / 2021
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Copenhagen, DK and Boston, MA, U.S., June 11, 2021 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.
Please see the attached files.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development. Zealand markets V-Go®, abasal-bolus insulin delivery option for people with diabetes and has received approval for Zegalogue® (dasiglucagon), the first and only glucagon analogue for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 and above. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics. Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit www.zealandpharma.com.
Forward-Looking Statement
The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.
For further information, please contact:
| Zealand Pharma Investor Relations |
| Claudia Styslinger |
| Argot Partners |
| investors@zealandpharma.com |
| Zealand Pharma Media Relations |
| David Rosen |
| Argot Partners |
| media@zealandpharma.com |
Attachments
FAQ
What recent transactions have occurred involving Zealand Pharma shares (ZEAL)?
What is Zealand Pharma's focus in biotechnology?
What are Zealand Pharma's marketed products?
How many drug candidates has Zealand Pharma advanced into clinical development?
Who are Zealand Pharma's collaboration partners?
